"Unlike your bleach Brilacidin was well tolerated."
(Not my bleach, as you know).
If you call only a minority of the folks suffering peripheral neuropathy were badly affected, means it was "well-tolerated", then I guess that's true, at least in IPIX land:
"Brilacidin-related adverse events of tingling (paresthesia) and hypoesthesia (numbness), which are known, transient, mostly mild, non-serious adverse events related to Brilacidin IV treatment."
It's the ones that weren't mild that are of interest, in a series of only 60 patients treated with brilacidin. I wonder what the incidence of serious peripheral neuropathy or severe hypertension would be if brilacidin were ever to be used in hundreds or thosuands of patients.
And again, this statement from Ehrlich is an outright lie:
"Brilacidin showed promising treatment effects ...."
In this study brilacidin showed no effect whatsoever versus placebo in treating patients with COVID-19.
It completely failed its primary endpoints, and both secondary endpoint data and (the desperate and pathetic) retrospective data dredging are utterly invalid in these circumstances.
Ehrlich is committing blatant securities law violations by making this entirely false claim.
News 
Market Data 
Discover 
